BillionToOne Appoints Anthony Pagano to Board of Directors as Audit Committee Chair

Rhea-AI Summary

BillionToOne (NASDAQ: BLLN) announced the appointment of Anthony Pagano to its Board of Directors, effective January 1, 2026, and named him Chair of the Audit Committee.

Pagano is currently CFO and Executive Vice President of Genmab since March 2020 and previously joined Genmab in December 2007. During his tenure at Genmab, annual revenues grew from $100M to more than $3B. He began his career at KPMG, served in senior finance roles at NovaDel Pharma, is a Certified Public Accountant, holds a B.S. in Accounting and an M.B.A. from NYU Stern.

Company leaders said Pagano's financial experience will support BillionToOne's growth and governance as it advances its molecular diagnostics strategy.

Positive

• Board appointment effective January 1, 2026
• Named Audit Committee Chair, strengthening governance
• Genmab background: revenue growth from $100M to >$3B
• Extensive finance leadership including CFO role since March 2020
• CPA credential and MBA from NYU Stern

Negative

• None.

News Market Reaction – BLLN

-5.32%

3 alerts

-5.32% Session close to close

+5.6% Peak Tracked

-10.4% Trough Tracked

$4.90B Market Cap

1.1x Rel. Volume

In the Dec 10 session, BLLN declined 5.32%, reflecting a notable negative market reaction. Argus tracked a peak move of +5.6% during that session. Argus tracked a trough of -10.4% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -5.3% in the session following this news. A negative reaction despite the addition o...

Analysis

The stock moved -5.3% in the session following this news. A negative reaction despite the addition of an experienced financial executive would contrast with prior positive responses to earnings and governance news, such as the 4.65% moves following Q3 results and related updates. The stock had been trading below its 200-day MA, so existing technical weakness may have amplified selling. Investors could also have focused on broader valuation or IPO-related volatility rather than the long-term governance benefit.

Key Figures

Genmab revenue start: $100M Genmab revenue later: more than $3B Q3 2025 revenue: $83.5M +5 more

8 metrics

Genmab revenue start $100M Genmab annual revenue at start of Pagano’s tenure

Genmab revenue later more than $3B Genmab annual revenue during Pagano’s tenure

Q3 2025 revenue $83.5M Total revenue in Q3 2025

Q3 revenue growth 117% Year-over-year total revenue growth in Q3 2025

IPO gross proceeds $314.0M Aggregate gross proceeds from Nov 7, 2025 IPO closing

200-day MA $106.84 200-day moving average before this news

Q3 gross margin 70% Gross margin in Q3 2025 vs 53% prior year

Market cap $4,708,295,663 Equity value before the appointment announcement

Historical Context

5 past events · Latest: Dec 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 09	Board appointment	Positive	+4.7%	Added experienced Genmab CFO to board and as Audit Committee Chair.
Dec 09	Earnings results	Positive	+4.7%	Reported strong Q3 revenue growth, margin expansion and positive income.
Dec 02	Earnings timing	Neutral	+1.7%	Announced date and webcast details for upcoming Q3 2025 results.
Nov 07	IPO closing	Positive	+2.2%	Closed upsized IPO with full overallotment exercise and Nasdaq listing.
Nov 06	IPO announcement	Positive	-8.2%	Detailed upsized IPO terms and proceeds as shares began Nasdaq trading.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news, particularly earnings, has generally seen positive price alignment, with one divergence around the IPO listing.

Recent Company History

This announcement adds a governance-focused milestone to BillionToOne’s recent trajectory. The company completed an upsized IPO in early November 2025, raising roughly $273.1M–$314.0M in gross proceeds. It then reported strong Q3 2025 results with rapid revenue growth and improving margins. On December 9, 2025, the same day as Q3 earnings, the company highlighted Anthony Pagano’s appointment, emphasizing his financial and life sciences experience to support its molecular diagnostics strategy.

Key Terms

molecular diagnostics, audit committee, antibody therapeutics, mergers & acquisitions, +1 more

5 terms

molecular diagnostics medical

"BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company"

Molecular diagnostics are laboratory tests that look for specific molecules — such as genes, pieces of DNA or RNA, or proteins — to detect disease, predict risk, or guide treatment choices. For investors, these tests matter because they can change how illnesses are diagnosed and treated, create recurring revenue through specialized tests and companion products, and face clear regulatory and reimbursement pathways that drive commercial value; think of them as reading a biological barcode to inform medical decisions.

audit committee financial

"appointment of Anthony Pagano to its Board ... serve as Chair of the Audit Committee"

A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.

antibody therapeutics medical

"developing, launching and commercializing differentiated and innovative antibody therapeutics"

Antibody therapeutics are medicines made from proteins the immune system uses, engineered to stick to specific molecules or cells to block disease or mark them for removal. They matter to investors because successful antibody drugs can command high prices and large markets, but their value hinges on clinical trial outcomes, manufacturing complexity, regulatory approval and patent protection—like custom-made keys that can open big rewards or be hard to replicate.

mergers & acquisitions financial

"provided audit and mergers & acquisitions consulting services to a diverse client base"

Mergers & acquisitions are deals in which one company buys another or two companies combine into one, like two households joining to share costs or a family buying a neighbor’s house to expand. Investors care because these moves can change a company’s size, revenue and profit potential, alter its debt load, and create shortcuts to new markets or technologies — but they also bring risks such as integration problems and unexpected costs that can affect stock value.

certified public accountant financial

"Mr. Pagano is a Certified Public Accountant and holds a B.S. in Accounting"

A certified public accountant (CPA) is a licensed accounting professional who has passed rigorous exams and met education and experience requirements to prepare, review, and officially certify financial statements and tax filings. For investors, a CPA's involvement is like a neutral referee confirming that a company's reported numbers are accurate and follow accounting rules, which improves trust in financial reports and lowers the risk of unexpected errors or misleading information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MENLO PARK, Calif., Dec. 9, 2025 /PRNewswire/ – BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the appointment of Anthony Pagano to its Board of Directors, effective January 1, 2026. Mr. Pagano will also serve as Chair of the Audit Committee.

Mr. Pagano is currently Chief Financial Officer and Executive Vice President of Genmab, a leading international biotechnology company, a position he has held since March 2020. He joined Genmab in December 2007, establishing a strong track record of driving financial performance and strategic growth throughout his tenure. During Mr. Pagano's tenure, Genmab has grown from $100M in annual revenues to more than $3B, developing, launching and commercializing differentiated and innovative antibody therapeutics that improve the lives of patients.

Before his role at Genmab, Mr. Pagano served as Corporate Controller and Senior Director of Business Planning for NovaDel Pharma, a publicly traded specialty pharma company. He started his professional career at KPMG LLP, where he advanced to Manager and provided audit and mergers & acquisitions consulting services to a diverse client base spanning startups to Fortune 500 corporations across multiple industries.

Mr. Pagano is a Certified Public Accountant and holds a B.S. in Accounting from The College of New Jersey and an M.B.A. from the Stern School of Business at New York University.

"BillionToOne is at the forefront of precision diagnostics, and I am honored to support this important mission," said Anthony Pagano. "Having witnessed the power of innovation in life sciences throughout my career, I am impressed by BillionToOne's technology and team. I look forward to working with the Board and management as the company enters its next phase of growth."

"Anthony's appointment significantly strengthens our Board," said Dr. Oguzhan Atay, co-founder and CEO of BillionToOne and Chairman of the Board. "I believe his deep financial acumen and proven leadership in guiding high-growth life sciences companies will be instrumental in our mission to create a category-defining, transformative molecular diagnostics company."

About BillionToOne
Headquartered in Menlo Park, California, BillionToOne is a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all. The company's patented Quantitative Counting Templates™ (QCT™) molecular counting platform is the only multiplex technology that can accurately count DNA molecules at the single-molecule level. For more information, visit www.billiontoone.com.

Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of federal securities laws. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements in this press release include, but are not limited to, statements regarding the company's future growth and advancement of its diagnostic technologies. These statements are based on management's current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, some of which are beyond BillionToOne's control. These and additional risks and uncertainties could affect BillionToOne's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. These risks and uncertainties include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in BillionToOne's prospectus filed with the Securities and Exchange Commission on November 6, 2025. The forward-looking statements in this press release are based on information available to BillionToOne as of the date hereof, and BillionToOne disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing BillionToOne's views as of any date subsequent to the date of this press release.

Investor Contact
ir@billiontoone.com 

Media Contact
billiontoone@moxiegrouppr.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/billiontoone-appoints-anthony-pagano-to-board-of-directors-as-audit-committee-chair-302637038.html

SOURCE BillionToOne

FAQ

When does Anthony Pagano join BillionToOne's board (BLLN)?

Anthony Pagano's board appointment is effective January 1, 2026.

What role will Anthony Pagano hold at BillionToOne (BLLN)?

He will serve as a member of the Board and as Chair of the Audit Committee.

What finance experience does Pagano bring to BillionToOne (BLLN)?

Pagano is CFO and EVP of Genmab since March 2020 and previously held senior finance roles, with a track record of scaling revenues.

How large did Genmab grow under Pagano's tenure cited in the announcement?

The announcement states Genmab's annual revenues grew from $100M to more than $3B during his tenure.

Does Anthony Pagano hold professional qualifications relevant to audit oversight at BLLN?

Yes; he is a Certified Public Accountant and holds an M.B.A. from NYU Stern.